300006 莱美药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.343-7.419-4.439-0.425-3.210
总资产报酬率 ROA (%)-0.883-4.961-3.056-0.300-2.297
投入资产回报率 ROIC (%)-1.056-5.902-3.623-0.360-2.799

边际利润分析
销售毛利率 (%)51.90355.76864.38869.33073.498
营业利润率 (%)-6.332-18.844-13.3016.278-10.857
息税前利润/营业总收入 (%)-7.568-20.209-11.865-2.123-7.963
净利润/营业总收入 (%)-6.465-16.312-10.066-1.119-8.624

收益指标分析
经营活动净收益/利润总额(%)43.78752.885115.869-2,145.438151.840
价值变动净收益/利润总额(%)82.86614.40224.9912,421.015-7.682
营业外收支净额/利润总额(%)0.9570.438-40.090-1,464.312-27.631

偿债能力分析
流动比率 (X)1.9852.0882.2082.9282.489
速动比率 (X)1.7771.8671.9572.6242.201
资产负债率 (%)35.95931.48534.05226.59128.483
带息债务/全部投入资本 (%)22.72317.61620.73611.57914.840
股东权益/带息债务 (%)335.373461.123376.362735.392568.487
股东权益/负债合计 (%)176.239216.603192.839270.667244.128
利息保障倍数 (X)6.44515.7565.0050.841-14.654

营运能力分析
应收账款周转天数 (天)108.866116.208134.811131.612153.285
存货周转天数 (天)180.937190.452236.777244.692276.541